Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11817616 | 0.97 | LMNA (0.36) | LMNA | |
| SCHEMBL18130241 | 0.97 | LMNA (0.36) | LMNA | |
| SCHEMBL15352117 | 0.97 | LMNA (0.36) | LMNA | |
| SCHEMBL6358198 | 0.97 | LMNA (0.36) | LMNA | |
| SCHEMBL1685090 | 0.90 | — | — | |
| SCHEMBL672220 | 0.80 | LMNA (0.42) | LMNA | |
| SCHEMBL1558945 | 0.78 | LMNA (0.33) | LMNA | |
| SCHEMBL15351958 | 0.77 | — | — | |
| SCHEMBL163948 | 0.76 | — | — | |
| SCHEMBL1559823 | 0.75 | LMNA (0.32) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250343048-A1 | ETCHING METHOD | RESONAC CORPORATION (JP) | 2025-11-06 | — | — | US | disclosed |
| US-20250145551-A1 | SYNTHESIS OF HFO-153-10MCZZ INCLUDING CATALYTIC COUPLING OF HCFC-225CA OR CFC-215CB | THE CHEMOURS COMPANY FC, LLC (US) | 2025-05-08 | — | — | US | disclosed |
| EP-4482909-A2 | SYNTHESIS OF HFO-153-10MCZZ INCLUDING CATALYTIC COUPLING OF HCFC-225CA OR CFC-215CB | The Chemours Company FC, LLC (US) | 2025-01-01 | — | — | EP | disclosed |
| EP-4481794-A1 | ETCHING METHOD | Resonac Corporation (JP) | 2024-12-25 | — | — | EP | disclosed |
| CN-119019743-A | Use of fluorine-containing alkyne and foaming agent composition containing fluorine-containing alkyne | 泉州宇极新材料科技有限公司 | 2024-11-26 | — | — | CN | disclosed |
| CN-118679554-A | Etching method | 株式会社力森诺科 | 2024-09-20 | — | — | CN | disclosed |
| WO-2023164093-A2 | SYNTHESIS OF HFO-153-10MCZZ INCLUDING CATALYTIC COUPLING OF HCFC-225CA OR CFC-215CB | THE CHEMOURS COMPANY FC, LLC (US) | 2023-08-31 | — | — | WO | disclosed |
| WO-2023157441-A1 | ETCHING METHOD | 株式会社レゾナック | 2023-08-24 | — | — | WO | disclosed |
| WO-2020161072-A1 | PROCESS FOR MANUFACTURING QUANTUM DOTS | UNIVERSITEIT VAN AMSTERDAM (NL) | 2020-08-13 | — | — | WO | disclosed |
| EP-3693439-A1 | METHOD FOR MANUFACTURING QUANTUM DOTS | Universiteit van Amsterdam (NL) | 2020-08-12 | — | — | EP | disclosed |
| US-5650156-A | ENCAPSULATION OF DRUGS, MICROPARTICLES, MICROEMULSIONS, SHELL CROSSLINKED BY DISULFIDE BONDS | VIVORX PHARMACEUTICALS, INC. (US) | 1997-07-22 | — | — | US | disclosed |
| US-5639473-A | SUBJECTING AQUEOUS MEDIUM CONTAINING BIOCOMPATIBLE MATERIAL CAPABLE OF BEING CROSSLINKED BY DISULFIDE BONDS AND NUCLEIC ACID CONSTRUCT TO HIGH INTENSITY ULTRASOUND WAVES | VIVORX PHARMACEUTICALS, INC. (US) | 1997-06-17 | — | — | US | disclosed |
| US-5635207-A | SUBJECTING AQUEOUS MEDIUM CONTAINING OXYGEN BINDING PROTEIN TO HIGH INTENSITY ULTRASOUND CONDITIONS TO PROMOTE CROSSLINKING AND FORM POLYMERIC SHELL OF SPECIFIED SIZE | VIVORX PHARMACEUTICALS, INC. (US) | 1997-06-03 | — | — | US | disclosed |
| WO-1996039702-A2 | METHODS AND AGENTS FOR THE EXTRACTION OF CESIUM AND STRONTIUM FROM NUCLEAR WASTE | COREMETALS RESEARCH, INC. (US) | 1996-12-12 | — | — | WO | disclosed |
| WO-1996033132-A1 | EXTRACTION OF CESIUM AND STRONTIUM IONS FROM NUCLEAR WASTE | COREMETALS RESEARCH, INC. (US) | 1996-10-24 | — | — | WO | disclosed |
| US-5512268-A | CONTRAST AGENTS ENCAPSULATED IN BIOCOMPATIBLE POLYMER SHELL CROSSLINKED WITH DISULFIDE LIKAGE | VIVORX PHARMACEUTICALS, INC. (US) | 1996-04-30 | — | — | US | disclosed |
| US-5508021-A | BIOCOMPATIBLE CROSSLINKED POLYMER CONTAINING IMAGING AGENT | VIVORX PHARMACEUTICALS, INC. (US) | 1996-04-16 | — | — | US | disclosed |
| US-5505932-A | CONTAINING CONTRAST AGENT | VIVORX PHARMACEUTICALS, INC. (US) | 1996-04-09 | — | — | US | disclosed |
| US-5498421-A | IN A POLYMERIC SHELL CONTAINING SULFHYDRYL AND/OR DISULFIDE GROUPS | VIVORX PHARMACEUTICALS, INC. (US) | 1996-03-12 | — | — | US | disclosed |
| US-5362478-A | Shell comprising biocompatible naturally occurring polymer which is crosslinked by disulfide bonds and which, before crosslinking, has covalently attached sulfhydryl or disulfide groups | VIVORX PHARMACEUTICALS, INC. (US) | 1994-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250145551-A1 | SYNTHESIS OF HFO-153-10MCZZ INCLUDING CATALYTIC COUPLING OF HCFC-225CA OR CFC-215CB | HCFC1, CCRL2, CCR3 | LMNA 3186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.